Association of ovarian and uterine cancers with postmenopausal hormonal treatments

Clinical Obstetrics and Gynecology

Volumn 51, Issue 3, 2008, Pages 607-617

  Neves E Castro, M ^a  

^a Clinica de Feminologia Holistica   (Portugal)

Author keywords

Hormonal introgenesis; HRT; Ovarian cancer; Uterine cancer

Indexed keywords

ESTROGEN; GESTAGEN; RALOXIFENE; TAMOXIFEN; TIBOLONE; PREGNANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM SARCOMA; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; OSTEOPOROSIS; OVARY CANCER; TRANSVAGINAL ECHOGRAPHY; TREATMENT CONTRAINDICATION; UTERINE CERVIX CANCER; UTERUS CANCER; UTERUS SARCOMA; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; FEMALE; METHODOLOGY; OVARY TUMOR; POSTMENOPAUSE; REVIEW; RISK FACTOR;

ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; NORPREGNENES; OVARIAN NEOPLASMS; POSTMENOPAUSE; PROGESTINS; RALOXIFENE; RISK FACTORS; TAMOXIFEN; UTERINE NEOPLASMS;

EID: 54449097080     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318180b988     Document Type: Article

References (62)

1. IMS. Hormone replacement therapy in climacteric and aging brain. Climacteric. 2001;4:181-193.
2. Kotsopoulos J, Lubinski J, Neuhausen SL, et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Endocrinol. 2006;100:83-88.
3. Beral V, Bull D, Million Women Study Collaborators, et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369: 1703-1710.
4. Neves-e-Castro M. An analysis of ovarian cancer in the Million Women Study. Gynecol Endocrinol. 2007;23:410-413.
5. Shapiro S. False alarm: postmenopausal hormone therapy and ovarian cancer. Climacteric. 2007;10:466-470.
6. Gompel A, Plu-Bureau G. Ovarian cancer and hormone replacement therapy [correspondence]. Lancet. 2007;370:932.
7. Neves-e-Castro M. The Million Women Study and breast cancer. Maturitas. 2003; 46:1-6.
8. Smith EM, Ritchie JM, Levy BT, et al. Prevalence and persistence of human papillomavirus in postmenopausal aged women. Cancer Detect Prev. 2003;27: 472-480.
9. The International Menopause Societyposition paper. Hormone replacement therapy and cancer. Climacteric. 2001; 4:181-193.
10. Marchetti M, Vasile C, Chiarelli S. Endometrial cancer: asymptomatic endometrial findings characteristics of post menopause endometrial cancer. Eur J Gynecol Oncol. 2005;26:479-484.
11. ItoK.Hormone replacement therapy and cancers: the biological roles of estrogens and progestin in tumorigenesis are different between the endometrium and breast. Tohoku J. Exp Med. 2007;212:1-12.
12. Grady D, Gebretsadik T, Kerlokowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obst Gynecol. 1995;85:304-313.
13. Ulrich LG. HRT and endometrial cancer. Presented at the 12th World Congress on the Menopause, Madrid, May, 2008. Climacteric. 2008 (suppl).
14. Wildemeersch D, Pylyser K, De Wever N, et al. Endometrial safety after 5 years of continuous combined transdermal estrogens and intrauterine levonorgestrel delivery for postmenopausal hormone substitution. Maturitas. 2007;57:205-209.
15. Wildemeersh D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel releasing intrauterine system: long-term follow up. Maturitas. 2007;57:210-213.
16. Ørbo A, Rise CE, Mutter GL. Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res. 2006;66:5613-5617.
17. Kresowik J, Ryan GL, Van Voorthis BJ. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intraute-rine system. Obstet Gynecol. 2008;111: 547-549.
18. Strom BL, Schinnar R, Weber AL, et al. Case control study of postmenopausal hormone replacement therapy and endo-metrial cancer. Am J Epidemiol. 2006;164: 775-786.
19. Beral V, Bull D, Reeves G. Million Women Study Collaborators. Endometrial cancer and hormone replacement therapy in the Million Women Study. Lancet. 2005;365:1543-1551.
20. Di Spiezio Scardo A, Radhakrishnan S. Endometrial carcinoma on continuous combined HRT case report and literature review. Maturitas. 2004;48:171-175.
21. Lacey JV Jr, Brinton LA, Lubin JH, et al. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Prev Cancer Epidemiol Biomarkers. 2005;14: 1724-1731.
22. Doherty JA, Cushning-Haugen KL, Saltzman BS, et al. Long-term use postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol. 2007;197:139.e1-139.e7.
23. Freeley KM, Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol. 2001;54:435-440.
24. SamsioeG, BoschitschE, Concin H, etal. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. Climacteric. 2006;9:368-379.
25. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004;47: 277-283.
26. Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with "bioidentical" hormone replacement therapy. Med J Aust. 2007;187: 244-245.
27. Yeh IT. Postmenopausal hormone replacement therapy; endometrial and breast effects. Adv Anat Pathol. 2007;14:17-24.
28. McGurgan P, Taylor JL, Duffy SR, et al. An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to HRT. Maturitas. 2006;53:454-461.
29. Mia H Jr, Maltez H, Studard E, et al. Effect of previous hormone replacement therapy on endometrial polyps during menopause: a study based on the expression of Ki-67, bcl-2 and c-erl. B2. Gynecol Endocrinol. 2004;18:299-304.
30. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007;92:911-918.
31. The Million Women Study Collaborators. Endometrial cancer and hormone replacement therapy in the Million Women study. Lancet. 2005;365:1543-1551.
32. Shapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric. 2004; 7:3-7.
33. Sturdee DW. Comment on Endometrial cancer in the Million Women Study. IMS http://www.imsociety.org (May 12, 2005).
34. Wiegratz I, Kuhl H. Endometrial cancer and hormone-replacement therapy [correspondence]. Lancet. 2005;366:201.
35. Kurtay G, Berker B, Demirel C. Transvaginal ultrasonographic assessment of the endometrium in asymptomatic post-menopausal women using different HRT regimens using tibolone or estrogen. J Reprod Med. 2004;49:893-898.
36. Nassar AH, Khalil AM, Seoud MA, et al. Endometrial adenoma carcinoma after prolonged tibolone therapy. Int J Gynecol Obstet. 2005;90:78-79.
37. Velthuis-te W, Erica JM, Hendricks PT, et al. Preferential prescribing of tibolone and combined estrogen plus progestagen therapy in postmenopausal women. Menopause. 2007;14:518-527.
38. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst. 1995;87:645-651.
39. Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527-537.
40. Kedar RP, Bourne TH, Powles JP, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet. 1994;343:1318-1321.
41. Bonilla-Musoles F, Raga F, Osborne NG, et al. Three-dimensional hysterosonography for the study of endometrial tumours: comparison with conventional transvaginal sonography, hysterosalpingography and hysteroscopy. Gycnecol Oncol. 1997;65:245-252.
42. Suh-Burgmann EJ, Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. A Review. Ann Intern Med. 1999;131:127-135.
43. Watson P, Vasen HF, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med. 1994;96:516-520.
44. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007;25:5158-5164.
45. Mcgurgan P, Taylor LJ, Duffy SR, et al. Does tamoxifen therapy affect the hormone receptor expression and cell proliferation indices of endometrial polyps? An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to tamoxifen. Maturitas. 2006;54:252-259.
46. Biron-Shental T, Tepper R, Fishman A, et al. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol. 2003;90: 382-386.
47. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94: 256-266 and 2005;96:561.
48. Mourad M, Cote JF, Morel O, et al. Malignant mixed müllerian tumor of the uterus following tamoxifen for breast cancer: case report. Gynecol Obstet Fertil. 2008. In press.
49. Chan SS, Tam WH, Yeo W, et al. A randomized controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG. 2007; 114:1510-1515.
50. Ravazoula P, Androutsopoulos G, Zyli P, et al. A clinic pathology study on patients with endometrial cancer after adjuvant tamoxifen treatment for breast cancer: a single centre experience [Letter to the Editor]. Breast J. 2006;12:578-584.
51. Mourits MJ, Hollema H, De Vries EG, et al. Apoptosis and apoptosis associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol. 2002;33:341-346.
52. Liu IF, Yen YS, Chenh YM, et al. Mitotically active leiomyoma of the uterus in postmenopausal breast cancer patient receiving tamoxifen. Am J Obstet Gynecol. 2006;45:167-169.
53. Garcia-Perez MA, Noguera R, del Val R, et al. Comparative effects of estradiol, raloxifene, and genistein on the uterus of ovariectomyzed mice. Fertil Steril. 2006; 86:1003-1005.
54. Davis AM, Ellersieck MR, Grimm KM, et al. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene innormal and cancerous endometrial cell lines and in the murine uterus. Mol Reprod Dev. 2006;73:1034-1044.
55. BotsisD,Christodoulakos G, Papagianni V, et al. The effect of raloxifene and tibolone on the uterine blood flow and endometrial thickness: a transvaginal Doppler study. Maturitas. 2006;53: 362-368.
56. Christodoulakos GE, Botsis DS, Lambrinoudaki IV, et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas. 2006;53: 413-423.
57. Tsalikis T, Zepiridis L, Zafrakas L, et al. Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene. Maturitas. 2005;51: 215-218.
58. de Azevedo GD, do Prado MF, Ferriani RA, et al. Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study. Maturitas. 2004;47:195-200.
59. Goldstein SR. Update on raloxifene to prevent endometrial-breast cancer. Eur J Cancer. 2000;36(suppl 4):S54-S56.
60. Fugere P, Scheele WH, Shah A, et al. Uterine effects of raloxifene in comparison ith continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol. 2000;182:568-574.
61. Goldman NA, de los Angeles MM, Jones JG, et al. Malignant mixed mullerian tumour of the uterus in a patient taking raloxifene. Obstet Gynecol. 2005;105 (5 Pt 2):1278-1280.
62. Lindahl B, Andolf E, Ingvar C, et al. Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma. Anticancer Res. 2008;28:1259-1262.